Table 1 Baseline characteristics of patients included in the study
Mean (SD), n (%) | |
|---|---|
Gender: Male | 377 (71) |
Age, years | 66.9 (9.3) |
Current smoker, n (%) | 157 (30) |
BMI (kg/m2) | 26.00 (5.13) |
Unadjusted Charlson Score (n = 528) | 1.82 (1–16) |
BODE index (median; IQR) | 3 (1–4) |
6MWT (m) | 380.61 (104.69) |
Exacerbation rate | 2.05 (0–15) |
Severe exacerbation rate | 0.39 (0–8) |
Lung function (post-brd) | |
FEV1, in L | 1.40 (0.71) |
FVC, in L | 2.81 (0.89) |
FEV1/FVC% | 47.87 (13.97) |
FEV1, % predicted | 49.89 (16.8) |
FVC, % predicted | 80.70 (21.21) |
Collagen markers [ng/ml] | |
C3M | 30.54 (12.61) |
C6M | 15.25 (8.62) |
Pro-C3 | 13.29 (10.03) |
Pro-C6 | 8.76 (4.31) |
EL-NE | 7.78 (6.78) |
GOLD Gradea | |
GOLD II | 262 (50) |
GOLD III | 180 (35) |
GOLD IV | 80 (15) |
rs8099917 genotypes | |
TT | 339 (65) |
GG | 26 (5) |
TG | 155 (30) |
rs12979860 genotypes | |
CC | 76 (30) |
TT | 45 (18) |
TC | 131 (52) |
MMRC score (median; IQR) | 2 (1–2) |
Inflammation markers at baseline | |
Copeptin, pMol/L | 12.57 (16.66) |
Adrenomedullin, nMol/L | 0.69 (0.38) |
Atrial Natriuretic Peptide, pMol/L | 113.67 (101.03) |
Procalcitonin, μg/l | 0.09 (0.14) |
SF-36 | |
Physical function | 51.54 (25.94) |
Role physical | 51.05 (43.48) |
Role emotional | 66.26 (43.52) |
Social Functioning | 69.49 (28.56) |
Mental Health | 64.89 (20.07) |
Body Pain | 74.19 (27.94) |
Vitality | 51.79 (21.00) |
General Health | 47.88 (22.90) |
SGRQ | |
Symptoms score | 49.30 (22.65) |
Activity score | 57.22 (22.90) |
Impacts score | 32.11 (18.66) |
Total score | 42.39 (18.11) |